PL1648427T3 - Leczenie zaburzeń demielinizacyjnych niskimi dawkami przeciwciała IgM - Google Patents

Leczenie zaburzeń demielinizacyjnych niskimi dawkami przeciwciała IgM

Info

Publication number
PL1648427T3
PL1648427T3 PL04752450T PL04752450T PL1648427T3 PL 1648427 T3 PL1648427 T3 PL 1648427T3 PL 04752450 T PL04752450 T PL 04752450T PL 04752450 T PL04752450 T PL 04752450T PL 1648427 T3 PL1648427 T3 PL 1648427T3
Authority
PL
Poland
Prior art keywords
low dose
antibody treatment
igm antibody
demyelinating disorders
demyelinating
Prior art date
Application number
PL04752450T
Other languages
English (en)
Inventor
Elliot A Gruskin
Eric Chojnicki
Arthur E Warrington
Allan J Bieber
Moses Rodriguez
Original Assignee
Mayo Found Medical Education & Res
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res, Acorda Therapeutics Inc filed Critical Mayo Found Medical Education & Res
Publication of PL1648427T3 publication Critical patent/PL1648427T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04752450T 2003-05-16 2004-05-17 Leczenie zaburzeń demielinizacyjnych niskimi dawkami przeciwciała IgM PL1648427T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47123503P 2003-05-16 2003-05-16
PCT/US2004/015436 WO2004110355A2 (en) 2003-05-16 2004-05-17 Compositions and methods including a recombinant human mab that promotes cns remyelination
EP04752450.9A EP1648427B1 (en) 2003-05-16 2004-05-17 Low dose IgM antibody treatment of demyelinating disorders

Publications (1)

Publication Number Publication Date
PL1648427T3 true PL1648427T3 (pl) 2014-05-30

Family

ID=33551425

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04752450T PL1648427T3 (pl) 2003-05-16 2004-05-17 Leczenie zaburzeń demielinizacyjnych niskimi dawkami przeciwciała IgM

Country Status (8)

Country Link
US (5) US8460665B2 (pl)
EP (1) EP1648427B1 (pl)
JP (1) JP2007505157A (pl)
AU (2) AU2004247021A1 (pl)
CA (2) CA2967294C (pl)
ES (1) ES2451993T3 (pl)
PL (1) PL1648427T3 (pl)
WO (1) WO2004110355A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509235A (ja) * 2006-11-03 2010-03-25 ノースウェスタン ユニバーシティ 多発性硬化症の治療
WO2009104100A2 (en) * 2008-02-19 2009-08-27 Patrys Limited Antibody combinations, and methods of making and using same
NZ624752A (en) * 2010-10-19 2015-11-27 Mayo Foundation Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
US9150867B2 (en) 2011-04-28 2015-10-06 Mayo Foundation For Medical Education And Research DNA aptamers for promoting remyelination
US20150104460A1 (en) 2012-04-17 2015-04-16 Mayo Foundation For Medical Education And Research Human Antibodies and Specific Binding Sequences Thereof for use in Stroke and Ischemia or Ischemic Conditions
EP3215190A4 (en) 2014-11-07 2018-10-31 Mayo Foundation for Medical Education and Research Treatment of neonatal hypoxia including impairments or effects thereof
US11999778B2 (en) 2016-05-13 2024-06-04 The Board Of Regents Of The University Of Texas System VH4 antibodies and compositions comprising the same
EP3401682A1 (en) * 2017-05-09 2018-11-14 Université de Nantes Diagnosis, prevention and treatment of demyelinating disorders of the central nervous system
US12037590B2 (en) 2018-12-06 2024-07-16 Mayo Foundation For Medical Education And Research Short DNA aptamers and methods for promoting remyelination

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US5256771A (en) 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
US7473423B2 (en) * 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US5591629A (en) * 1994-04-29 1997-01-07 Mayo Foundation For Medical Education & Research Monoclonal antibodies which promote central nervous system remyelination
EP2287190B1 (en) 2000-05-10 2014-12-17 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
JP2008127346A (ja) 2006-11-22 2008-06-05 Toshitsu Kagaku Kenkyusho:Kk 自己免疫疾患、炎症および神経疾患を治療および予防するための医薬

Also Published As

Publication number Publication date
US20180179277A1 (en) 2018-06-28
CA2525917C (en) 2017-07-04
AU2010202111A1 (en) 2010-06-17
US20070086999A1 (en) 2007-04-19
EP1648427A4 (en) 2007-04-11
US20130309240A1 (en) 2013-11-21
CA2525917A1 (en) 2004-12-23
EP1648427A2 (en) 2006-04-26
WO2004110355A3 (en) 2006-05-18
AU2010202111B2 (en) 2012-11-15
WO2004110355A2 (en) 2004-12-23
AU2004247021A1 (en) 2004-12-23
US20150299316A1 (en) 2015-10-22
US8968735B2 (en) 2015-03-03
ES2451993T3 (es) 2014-03-28
US20200247883A1 (en) 2020-08-06
CA2967294C (en) 2020-04-28
CA2967294A1 (en) 2004-12-23
EP1648427B1 (en) 2013-12-18
JP2007505157A (ja) 2007-03-08
US9751943B2 (en) 2017-09-05
US8460665B2 (en) 2013-06-11

Similar Documents

Publication Publication Date Title
TWI347951B (en) Therapeutic human anti-il-1r1 monoclonal antibody
SI2359856T1 (sl) Formulacija humanih protiteles za zdravljenje motenj, povezanih s TNF-alfa
IL173386A0 (en) Use of adcc-optimized antibodies for treating weak patients
EP1482972A4 (en) TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES
IL212419A0 (en) Methods of administering anti-tnf antibodies
EP1578988A4 (en) TNF-ALPHA VARIANT-BASED PROTEIN FOR TREATMENT OF TNF-ALPHA ASSOCIATED DISORDERS
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
IL174232A0 (en) Combinations of drugs for the treatment of neoplasms
PL375532A1 (pl) Związki benzimidazol-1-ilotiofenowe do leczenia nowotworów
IL169332A0 (en) Compounds for the treatment of metabolic disorders
ZA200500618B (en) Combinations of drugs for the treatment of neoplasms
GB0329874D0 (en) Compounds useful for the treatment of diseases
EP1658072A4 (en) Compounds for the Treatment of Neurodegenerative Diseases
AU2003251904A8 (en) Combinations of drugs for the treatment of neoplasms
EP1549343A4 (en) PROCESS FOR TREATING NEPHRITIS WITH ANTI-PDGF-DD ANTIBODIES
PL1648427T3 (pl) Leczenie zaburzeń demielinizacyjnych niskimi dawkami przeciwciała IgM
AU2003251875A8 (en) Combination therapy for the treatment of neoplasms
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
IL175412A0 (en) Use of specific histones for the treatment of parasitic diseases
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
AU2003295504A8 (en) Development of therapeutics for the treatment of endotoxin-mediated diseases
GB0222282D0 (en) Therapeutic device for the treatment of symptons caused by diseases
GB0315877D0 (en) Compounds for the treatment of disease
GB0325986D0 (en) Inhibitors of a-synuclein aggregation for the treatment of a-synuclein-related diseases
GB0305343D0 (en) Therapeutic agents for the treatment of bone disorders